Integrin αIIbβ3: from discovery to efficacious therapeutic target
about
Integrin-based therapeutics: biological basis, clinical use and new drugsThe Concise Guide to PHARMACOLOGY 2013/14: catalytic receptors.Platelet 12-LOX is essential for FcγRIIa-mediated platelet activation.Targeting integrin and integrin signaling in treating thrombosis.αIIbβ3 variants defined by next-generation sequencing: predicting variants likely to cause Glanzmann thrombasthenia.Efficacy and safety of eptifibatide versus tirofiban in acute coronary syndrome patients: A systematic review and meta-analysis.Salvianolic Acid Exerts Cardioprotection through Promoting Angiogenesis in Animal Models of Acute Myocardial Infarction: Preclinical EvidencePlatelets and their chemokines in atherosclerosis-clinical applications.Direct interaction of kindlin-3 with integrin αIIbβ3 in platelets is required for supporting arterial thrombosis in mice.RUC-4: a novel αIIbβ3 antagonist for prehospital therapy of myocardial infarctionRising like the phoenix?Effective components of Panax quinquefolius and Corydalis tuber protect the myocardium by inhibiting platelet activation and improving the hypercoagulable stateInhibition of αIIbβ3 Ligand Binding by an αIIb Peptide that Clasps the Hybrid Domain to the βI Domain of β3.Platelet-neutrophil interactions under thromboinflammatory conditionsCoagulation-driven platelet activation reduces cholestatic liver injury and fibrosis in mice.The Structure of a Full-length Membrane-embedded Integrin Bound to a Physiological LigandPlatelets in hemostasis and thrombosis: Novel mechanisms of fibrinogen-independent platelet aggregation and fibronectin-mediated protein wave of hemostasis.Identification of indothiazinone as a natural antiplatelet agent.Characterization of a Novel Integrin Binding Protein, VPS33B, Which Is Important for Platelet Activation and In Vivo Thrombosis and Hemostasis.A novel class of ion displacement ligands as antagonists of the αIIbβ3 receptor that limit conformational reorganization of the receptor.A talin mutant that impairs talin-integrin binding in platelets decelerates αIIbβ3 activation without pathological bleeding.The role of integrins in the trabecular meshwork.What is the role of genetic testing in the investigation of patients with suspected platelet function disorders?The Rap1-RIAM-talin axis of integrin activation and blood cell functionT4 bacteriophage-mediated inhibition of adsorption and replication of human adenovirus in vitro.Two case of preoperative bridging therapy for patients undergoing non-cardiac surgery after coronary stent implantation.Platelet sequestration and activation during GalTKO.hCD46 pig lung perfusion by human blood is primarily mediated by GPIb, GPIIb/IIIa, and von Willebrand Factor.Why do we study animal toxins?The integrin PSI domain has an endogenous thiol isomerase function and is a novel target for antiplatelet therapy.Impact of atrial fibrillation on platelet gene expression.The colonic metabolites dihydrocaffeic acid and dihydroferulic acid are more effective inhibitors of in vitro platelet activation than their phenolic precursors.The human platelet antigen-1b variant of αIIbβ3 allosterically shifts the dynamic conformational equilibrium of this integrin toward the active state.An αIIb β3 antagonist prevents thrombosis without causing Fc receptor γ-chain IIa-mediated thrombocytopenia.Synergistic effect of peptide inhibitors derived from the extracellular and intracellular domain of αIIb subunit of integrin αIIbβ3 on platelet activation and aggregation.A Short Half-Life αβ₃ Antagonist ANTP266 Reduces Thrombus Formation
P2860
Q26773026-6D290A51-09C7-4B6F-8BC8-E4B105CCB466Q30486741-901987C9-AFAF-4106-8207-C88FC67441CDQ33416935-41788BDF-F07A-40EA-8611-8D3B745F5A66Q33417854-6D57213E-6A65-4E4C-A463-91A7059FB470Q33421611-3E76F863-D0D7-42DC-8F90-38A24828B986Q33441432-F426ECD1-F290-45C8-952F-6559C8A1305FQ33872958-419D1E4D-3FF0-4C27-8926-444940F20633Q34019069-6665725D-8CAA-4328-97E9-0A0493700AB9Q34204496-A2B1D971-0C3C-410E-9AA9-D97782FD00B4Q34267671-2B06B661-A3EF-46C3-AEBE-CA902BD92F9DQ34347772-BE055D08-9432-4229-9ED5-5929B003CBA0Q35159538-163A20E3-D0C2-4583-BA42-B8969DC7605FQ35762202-B269B9A7-55DA-4B37-8D8A-06627F8E39FDQ35779411-0994BB6C-D55F-40F5-BEA0-F787D6FD3F6EQ35806023-4567EF91-E3B3-4E12-A589-8984FEE63C4FQ36283927-DECBA087-D80C-40BE-B0EE-58934AA0CA07Q36325536-CE84A689-232E-41F9-9BFC-2FB48D28A274Q36354061-300000E0-87DC-4117-97CF-F49010360B5BQ36373441-1CED8D4D-DD7F-4E9C-9628-DCD3D46C0685Q37633983-C9A87A64-E555-4209-B718-B32EC47ECA22Q37723482-53396C72-D5AB-40AD-91A1-747AFFDFD12AQ38165217-95341CFF-F38F-4956-B698-FD4638B75C80Q38183490-8AB8F0EE-F127-493C-95DB-D3D003718998Q38840456-C8885DE1-1F23-4A99-88F2-AEAB66ADFCAEQ38888380-2F05153D-E5E0-4CB0-9A21-CE9501BB8AA1Q41265547-CE9B511B-0AE6-4CA4-A91A-81E3A61397A5Q41339114-5CFE6730-31B0-417D-BFC7-6743F8529792Q42957096-28792505-A103-4E77-80BC-2A736413D250Q46427663-62AB0D6E-0672-48E9-B302-579750484CF3Q48110678-BE4EE1E9-2732-4D9C-A7E3-DEA83164DA21Q48205435-6AF0B613-2FAC-49B5-A46F-89FA0D59DE8FQ49806464-EF98F7BD-02D8-4F16-9E03-51B81F3CFBB7Q50501826-3031796A-8B08-4851-8D53-D67BEC0D9AA0Q51082751-1E47F8FA-1F69-4539-B7C8-2012166863EFQ58798481-A91129A7-1454-44BF-8CBE-2D6A55E7B503
P2860
Integrin αIIbβ3: from discovery to efficacious therapeutic target
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Integrin αIIbβ3: from discovery to efficacious therapeutic target
@en
Integrin αIIbβ3: from discovery to efficacious therapeutic target.
@nl
type
label
Integrin αIIbβ3: from discovery to efficacious therapeutic target
@en
Integrin αIIbβ3: from discovery to efficacious therapeutic target.
@nl
prefLabel
Integrin αIIbβ3: from discovery to efficacious therapeutic target
@en
Integrin αIIbβ3: from discovery to efficacious therapeutic target.
@nl
P2093
P2860
P1433
P1476
Integrin αIIbβ3: from discovery to efficacious therapeutic target
@en
P2093
Edward F Plow
Kamila Bledzka
Susan S Smyth
P2860
P304
P356
10.1161/CIRCRESAHA.112.300570
P577
2013-04-01T00:00:00Z